TMCnet News
H3 Biomedicine to Present New Data from Recent Research Advancements at 2017 American Association of Cancer Research Annual MeetingH3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai's global Oncology Business Group, announced today that company scientists will present one oral and five poster presentations at the 2017 American Association of Cancer Research (AACR) Annual Meeting in Washington, D.C., which is being held from April 1-5, 2017. Presentations will include first disclosures and updates on H3's lead programs in clinical development; H3B-6454, H3B-8800 and H3B-6527. Additional presentations will cover a survey of spliceosome gene mutations in cancer in collaboration with TCGA, as well as new research defining mechanistic changes induced by new SF3B1 alterations observed in CLL and small molecule splicing modulator mechanism of action studies. Each of the five compounds to be presented are currently investigational agents that have not been approved for any indication. The accepted abstracts are listed below and now available online on the AACR conference website: http://www.abstractsonline.com/pp8/#!/4292 H3 Biomedicine AACR 2017 Presentations: ABSTRACT TITLE: Discovery and development of H3B-6545: A novel, oral, selective estrogen receptor covalent antagonist (SERCA) for the treatment of breast cancer. Session information: Oral presentation to be presented at New Drugs on the Horizon Session 1 on Sunday April 2, 2017 from 1 p.m. to 3 p.m. Location to be announced. ABSTRACT TITLE: H3B-8800, a novel orally available SF3b modulator, shows preclinical efficacy across spliceosome mutant cancers
Session Category: Experimental and Molecular Therapeutics Permanent Abstract Number: 1185 ABSTRACT TITLE: H3B-6527, a selective and potent FGFR4 inhibitor for FGF19-driven Hepatocellular Carcinoma
Session Category: Experimental and Molecular Therapeutics Poster Board Number: 15 Permanent Abstract Number: 3126 ABSTRACT TITLE: Survey of spliceosome gene mutations and associated splicing defects across 33 cancer types
Session information: Permanent Abstract Number: 383 ABSTRACT TITLE: Novel SF3B1 deletion mutations result in aberrant RNA splicing in CLL patients
Session Category: Molecular and Cellular Biology / Genetics Permanent Abstract Number: 4471 ABSTRACT TITLE: A chemogenomic approach reveals the action of splicing modulators at the branch point adenosine binding pocket defined by the PHF5A/SF3b complex
Session Category: Experimental and Molecular Therapeutics Permanent Abstract Number: 126 About H3B-8800 H3B-8800 is an oral, potent and selective small molecule modulator of splicing factor 3b subunit 1 (SF3B1) that is being developed by H3 Biomedicine as an anticancer therapeutic agent. In pre-clinical studies, H3B-8800 showed dose dependent modulation of canonical and aberrant splicing when dosed orally at tolerated doses. More importantly, oral administration of H3B-8800 demonstrated preferential antitumor activity in several pre-clinical xenograft models carrying spliceosome mutations. H3 Biomedicine's lead research and discovery programs in splicing are designed to develop drugs that target the vulnerabilities related to deregulated RNA homeostasis in cancer. About H3B-6527 H3B-6527 is a selective, orally bioavailable, and potent inhibitor of fibroblast growth factor receptor 4 (FGFR4) that is being investigated for the treatment of advanced hepatocellular carcinoma (HCC). Aberrant signaling through the FGF19-FGFR4 axis has been shown to drive tumor development and dependency in pre-clinical models of HCC. H3B-6527 has shown sustained tumor regressions in several preclinical models of HCC where FGF19-FGFR4 signaling is aberrantly activated. The safety and preliminary efficacy of H3B-6527 will be explored in patients that are selected using a companion diagnostic that identifies HCC with activated FGF19-FGFR4 pathway activity. About H3B-6545 H3B-6545 is an orally bioavailable, potent and selective small molecule modulator of wild-type and mutant Estrogen Receptor (ERa). Mutations in ERa are detected in up to 30% of patients that initially respond but subsequently relapse to anti-endocrine therapies. Current endocrine therapies are only partially effective in the ERa mutant setting and a significant proportion of endocrine-therapy resistant breast cancer metastases continue to remain dependent on ERa signaling for growth/survival indicating a critical need to develop the next generation of ERa antagonists. About H3 Biomedicine Inc. H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and was established as a subsidiary of Eisai's U.S. pharmaceutical operation Eisai Inc. Leveraging this collaboration with Eisai Co., Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit http://www.h3biomedicine.com/. View source version on businesswire.com: http://www.businesswire.com/news/home/20170309005644/en/ |
